# A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

> **NCT00157872** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 150 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MK0966; rofecoxib
- **DRUG:** Comparator: naproxen tablet 500 mg

## Key facts

- **NCT ID:** NCT00157872
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-07
- **Primary completion:** 2004-07-05
- **Final completion:** 2004-09-19
- **Target enrollment:** 150 (—)
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157872, "A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00157872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*